lunes, 28 de abril de 2014

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer : Nature Biotechnology : Nature Publishing Group

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer : Nature Biotechnology : Nature Publishing Group




Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

Nature Biotechnology
 
 
doi:10.1038/nbt.2892
Received
 
Accepted
 
Published online
 
Comprehensive analyses of cancer genomes promise to inform prognoses and precise cancer treatments. A major barrier, however, is inaccessibility of metastatic tissue. A potential solution is to characterize circulating tumor cells (CTCs), but this requires overcoming the challenges of isolating rare cells and sequencing low-input material. Here we report an integrated process to isolate, qualify and sequence whole exomes of CTCs with high fidelity using a census-based sequencing strategy. Power calculations suggest that mapping of >99.995% of the standard exome is possible in CTCs. We validated our process in two patients with prostate cancer, including one for whom we sequenced CTCs, a lymph node metastasis and nine cores of the primary tumor. Fifty-one of 73 CTC mutations (70%) were present in matched tissue. Moreover, we identified 10 early trunk and 56 metastatic trunk mutations in the non-CTC tumor samples and found 90% and 73% of these mutations, respectively, in CTC exomes. This study establishes a foundation for CTC genomics in the clinic.

No hay comentarios:

Publicar un comentario